List view / Grid view
1 May 2014 | By Biogen Idec
Biogen Idec announced that a post hoc analysis of data from the AFFIRM study shows TYSABRI® (natalizumab) significantly increased the proportion of relapsing-remitting multiple sclerosis patients with confirmed improvement in walking speed...
1 May 2014 | By Nova Laboratories
UK pharmaceutical firm Nova Laboratories has secured U.S Food and Drug Administration approval for its acute lymphoblastic leukaemia (ALL) product Xaluprine...
30 April 2014 | By Teva
Data provides promise for a twice-daily, acetaminophen-free hydrocodone designed with potential abuse-deterrent properties...
30 April 2014 | By Johnson & Johnson
Johnson & Johnson announced that its affiliate Janssen Pharmaceutica NV has entered into a novel collaboration with the Stichting International Dispensary Association...
30 April 2014 | By Boehringer Ingelheim
Boehringer Ingelheim Animal Health reinforces its commitment to support applied research for the improved control of PRRS (Porcine Reproductive and Respiratory Syndrome) in Europe...
30 April 2014 | By Biogen Idec
Additional real-world data show tolerability profile consistent with pivotal studies...
30 April 2014 | By Waters
Powerful alternative to LIMS offers seamless lab-to-business connection for science-driven organizations...
29 April 2014 | By BioMarin
The first and only drug designed to address Morquio A syndrome is now available in Europe and the UK for children and adults with this rare genetic condition...
29 April 2014 | By Gilead
Gilead Sciences, Inc. announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi® (sofosbuvir) 400 mg was administered for the treatment of chronic hepatitis C virus...
29 April 2014 | By Biogen Idec
Biogen Idec announced two-year data from its Phase 3 ADVANCE clinical trial for PLEGRIDY™ (peginterferon beta-1a) in people with relapsing forms of multiple sclerosis...
29 April 2014 | By The European Medicines Agency
In 2013, EudraVigilance received more than one million post-marketing expedited adverse-drug-reaction reports...
29 April 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the European Commission has granted marketing authorisation for Incruse® (umeclidinium)...
28 April 2014 | By Roche
First anti IL-6 receptor biologic now available for subcutaneous and intravenous administration for both monotherapy and combination therapy...
28 April 2014 | By Teva
Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced results from the Phase III SYNERGY trial...
28 April 2014 | By GlaxoSmithKline
GlaxoSmithKline and Medicines for Malaria Venture announced the start of a phase III global programme to evaluate the efficacy and safety of tafenoquine...
